<DOC>
	<DOC>NCT01817985</DOC>
	<brief_summary>This is a Phase 1 Open-Label, Parallel-Group, Single-Dose Study to evaluate the Pharmacokinetics of GS-5816 in subjects with normal hepatic function and moderate or severe hepatic impairment.</brief_summary>
	<brief_title>A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Diagnosis of chronic (&gt; 6 months), hepatic impairment. In the opinion of the Investigator, be in good health. Severe hepatic encephalopathy. Prior placement of a portosystemic shunt. Hepatorenal or hepatopulmonary syndrome. Suspicion of hepatocellular carcinoma.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hepatitis C (HCV) Infection</keyword>
	<keyword>Moderate Hepatic Impairment</keyword>
	<keyword>Severe Hepatic Impairment</keyword>
</DOC>